

WOAH Reference Laboratory Reports Activities 2025

This report has been submitted: 29 janvier 2026 17:50

LABORATORY INFORMATION

*Name of disease (or topic) for which you are a designated WOAH Reference Laboratory:	Aujeszký's disease
*Address of laboratory:	Anses, Laboratoire de Ploufragan-Plouzané-Niort
*Tel:	+33(0)296016205
*E-mail address:	Celine.DEBLANC@anses.fr
Website:	https://www.anses.fr/en
*Name (including Title) of Head of Laboratory (Responsible Official):	Dr ETERRADOSSI Nicolas
*Name (including Title and Position) of WOAH Reference Expert:	Dr DEBLANC Céline. Head of the National and WOAH Reference Laboratory for Aujeszký's disease
*Which of the following defines your laboratory? Check all that apply:	Governmental

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAH Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
ELISA gB	Yes	69	0
ELISA gE	Yes	77	0
Direct diagnostic tests			
PCR	Yes	58	0
Virus isolation	Yes	29	0

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOAH?

Yes

Type of reagent available	Related diagnostic testing	Produced/ imported	Quantity supplied nationwide (ml, mg)	Quantity supplied at international level (ml, mg)	Name of beneficiary WOAH Member Countries

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOAH Members?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient WOAH Member Countries	Country of recipients
Serum sub- standard						FRANCE, GERMANY,

Céline Deblanc - - FRANCE

ADV1 gB	ELISA gB	produced and provided	16 ML	26 ML	4	PORTUGAL, UNITED KINGDOM,
Serum sub- standard ADV1 gE	ELISA gE	produced and provided	10 ML	31 ML	5	FRANCE, GERMANY, PORTUGAL, SPAIN, UNITED KINGDOM,
Positive and negative sera	ELISA gB, ELISA gE and virus neutralisation test	produced and provided	14 ML	554 ML	5	FRANCE, GERMANY, SPAIN, SWITZERLAND, UNITED KINGDOM,
AD Virus	PCR	produced and provided	20 ML	54 ML	4	DENMARK, FRANCE, THE NETHERLANDS, UNITED KINGDOM,
Positive and negative organs	PCR, virus isolation	produced and provided	0	579 biological samples (weight unknown)	3	DENMARK, THE NETHERLANDS, UNITED KINGDOM,
WOAH-approved International Standard Serum "ADV1"	ELISA gB, ELISA gE and virus neutralisation test	provided	0	2,8 ML	2	ARGENTINA, SWITZERLAND,

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOAHO Members?

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOAHO Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

9. Did your laboratory validate vaccines according to WOAHO Standards for the designated pathogen or disease?

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOAHO Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAHO Member?

Yes

Name of the WOAHO Member Country receiving a technical consultancy	Purpose	How the advice was provided
SWITZERLAND	opinion on ELISA results	by email

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAHO Members other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	WOAHO Member Countries involved other than your country
Optimizing sampling protocols for Aujeszky's disease diagnostics	2024-2026 (18 months)	harmonization of sampling and diagnostics across partner institutes	- WBVR (Wageningen Bioveterinary Research) - APHA (Animal and Plant Health Agency) - SSI (Statens Serum Institut) - ANSES (French Agency for Food, Environmental and Occupational Health and Safety)	DENMARK THE NETHERLANDS UNITED KINGDOM

13. In exercising your activities, have you identified any regulatory research needs* relevant for WOA?H?

No

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

No

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:

The data are collected at national level by active and passive surveillance in domestic pigs, wild boars and other susceptible animals (dogs, cats, ...)

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

1

Deblanc C., Allain V., Oger A., Bourry O., Hervé S., Renson P., Rose N., Simon G., Le Potier M-F., Ravise J-F. 2025. Bilan de la surveillance de la maladie d'Aujeszky en élevages de suidés et chez les mammifères domestiques en France hexagonale et sur l'île de La Réunion en 2024 [Review of surveillance of Aujeszky's disease in mainland France and Reunion island in 2024]. Bulletin épidémiologique, santé animale et alimentation 106 (8) : 1-8.

b) International conferences:

0

c) National conferences:

2

Herbet V, Béven V, Hirschaud E, Bigault L, Le Roux A, Paboeuf F, Jarman M, Mittal B, Deblanc C, Hammond J, Blanchard Y, Di Placido M, Dory D. Sequencing of porcine antibody repertoires: identification of CDR3 marker sequences against pseudorabies virus infection. 2ème congrès du CIVVet; 14-15 avril; Nantes, France 2025.

Herbet V, Béven V, Hirschaud E, Bigault L, Le Roux A, Paboeuf F, Jarman M, Mittal B, Deblanc C, Hammond J, Blanchard Y, Di Placido M, Dory D. Kinetic profiling of pig antibody repertoires: CDRH3-based identification of pseudorabies-specific antibodies. 5ème workshop Centres Germinatifs; 20 juin; Saint-Malo, France 2025.

d) Other (Provide website address or link to appropriate information):

0

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA?H Members?

Yes

a) Technical visit : 1

b) Seminars : 0

c) Hands-on training courses: 0

d) Internships (>1 month) 0

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
A	THE NETHERLANDS	1

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO 17025	PDF	1-2250_attestation accreditation 17025 - 2024-2029.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
ELISA gB	COFRAC
ELISA gE	COFRAC
PCR	COFRAC
virus isolation	COFRAC

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

Our institute maintains a complete and functioning laboratory biological risk management system that ensures that the laboratory is in compliance with applicable local, national, regional, and international standards and requirements for biosafety and laboratory biosecurity (in accordance with the WOAH terrestrial Manual, Chapter 1.1.4).

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAH?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAH?

No

TOR10: NETWORK WITH WOAH REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAH Reference Laboratories designated for the same pathogen or disease?

Not applicable (only WOAH Reference Laboratory designated for the disease)

24. Are you a member of a network of WOAH Reference Laboratories designated for the same pathogen?

Not applicable (only WOAH Reference Laboratory designated for the disease)

25. Did you organise or participate in inter-laboratory proficiency tests with WOAH Reference Laboratories designated for the same pathogen during the past 2 years?

Not applicable (Only WOAH Reference Laboratory designated for the disease)

not applicable, we are the only WOAH Reference Laboratory for Aujeszky's disease

26. Did your laboratory collaborate with other WOAH Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Not applicable (only WOAH Reference Laboratory designated for the disease)

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAH Reference Laboratories for the same pathogen during the past 2 years?

Yes

Purpose for inter-laboratory test comparisons ¹	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Name of the test	WOAH Member Countries
in 2024: Aujeszky's disease	organizer	14	PCR	AUSTRIA, BELGIUM, CZECH REPUBLIC, DENMARK, GERMANY, HONG KONG, IRELAND, ITALY, LATVIA,

Céline Deblanc - - FRANCE

diagnosis by real-time PCR	✓				PORTUGAL, SERBIA, SPAIN, THE NETHERLANDS, UNITED KINGDOM,
in 2024: Aujeszky's Disease diagnosis by ELISA	participant	7	ELISA gB & ELISA gE		BELGIUM, FRANCE,
in 2025: Aujeszky's Disease diagnosis by ELISA	participant	7	ELISA gB & ELISA gE		BELGIUM, FRANCE,

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOA?H?

Yes

Kind of consultancy	Location	Subject (facultative)
revision of a WOA?H Manual chapter	remote	updating the "Aujeszky's disease" chapter of the Terrestrial Manual
Case definition	remote	updating the "Aujeszky's disease" chapter of the Terrestrial Code

29. Additional comments regarding your report:

Yes

Many countries, particularly in Europe and America, have achieved a free status regarding this disease in swine herds or have implemented control or eradication plans. ELISA and PCR methods are well established in routine use in national reference laboratories, and they do not require confirmatory tests from the WOA?H reference laboratory. We are eager to assist any country for diagnosis but we have not received any requests in 2025.